Study objectives: Indications for thrombolysis in normotensive patients with pulmonary embolism (PE), based on the presence of right ventricular (RV) overload during transthoracic echocardiography (TTE), are controversial. We checked whether the monitoring of cardiac troponin T (cTnT) might help in risk stratification by detecting patients with RV myocardial injury. Patients and design: We studied 64 normotensive patients (30 women and 34 men) with a mean (؎ SD) age of 61.3 ؎ 17 years and PE, who had undergone TTE for the assessment of RV overload. Plasma cTnT levels were measured quantitatively (detection limit, > 0.01 ng/mL) at hospital admission, and subsequently three times at 6-h intervals. Heparin therapy alone was used in 87.5% of patients, while 12.5% of patients received thrombolysis. Key words: echocardiography; mortality; pulmonary embolism; troponin Abbreviations: APTT ϭ activated partial thrombin time; CI ϭ confidence interval; CK ϭ creatine kinase; CKMB ϭ MB isoenzyme of creatine kinase; cTnT ϭ cardiac troponin T; IVC ϭ inferior vena cava; LV ϭ left ventricle, ventricular; OR ϭ odds ratio; PE ϭ pulmonary embolism; RV ϭ right ventricle, ventricular; RV/LV ϭ right ventricle diameter/left ventricle diameter ratio P ulmonary embolism (PE) is still one of the major causes of in-hospital mortality. 1 Progressive, irreversible, right ventricular (RV) failure has been reported to precipitate a fatal outcome. 2 Transmural RV infarctions had been found at autopsy in patients who died because of massive PE. 3 The assessment of cardiac plasma troponin levels revealed ventricular injury, especially in patients with massive PE who had hypotension or shock. 4 Moreover, elevated plasma troponin levels found also in patients with preserved systemic systolic pressure and echocardiographic signs of RV overload has suggested myocardial injury in this group of patients. 5 Although it has been proven that RV strain detected at echocardiography, even in normotensive patients with acute PE,
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ulmonary embolism (PE) is still one of the major causes of in-hospital mortality. 1 Progressive, irreversible, right ventricular (RV) failure has been reported to precipitate a fatal outcome. 2 Transmural RV infarctions had been found at autopsy in patients who died because of massive PE. 3 The assessment of cardiac plasma troponin levels revealed ventricular injury, especially in patients with massive PE who had hypotension or shock. 4 Moreover, elevated plasma troponin levels found also in patients with preserved systemic systolic pressure and echocardiographic signs of RV overload has suggested myocardial injury in this group of patients. 5 Although it has been proven that RV strain detected at echocardiography, even in normotensive patients with acute PE, is an independent risk factor for fatal outcome, 6 -9 treatment with thrombolysis based only on the presence of RV overload is still controversial. 8 -12 Therefore, new parameters have been searched for in
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order to identify a subgroup of normotensive patients who are at high risk and may benefit from more aggressive treatment. We checked whether the detection of ongoing RV myocardial injury by the monitoring of cardiac troponin T (cTnT) levels might help in the risk stratification of patients with PE.
Materials and Methods

Clinical Data
The study analyzed normotensive patients with acute PE. PE was confirmed by typical findings from contrast-enhanced spiral CT scanning, which was performed according to the previously described protocol 13 in 59 cases, or by high-probability lung scintigraphy in 5 cases according to the criteria of the Prospective Investigation of Pulmonary Embolism. 14 At hospital admission, systemic BP was measured with a mercury sphygmomanometer, and heart rate, 12-lead ECG, and transcutaneous pulse oximetry also were recorded. Patients whose systolic BP at hospital admission was below 90 mm Hg, those who required IV catecholamine infusion, ventilation support, or had undergone cardiopulmonary resuscitation were not included in the study. Thus, the study group comprised 64 normotensive, initially hemodynamically stable patients (30 women and 34 men) with a mean (Ϯ SD) age of 61.3 Ϯ 17 years and proven PE.
Echocardiographic Data
In order to assess the degree of RV overload at hospital admission, all patients underwent transthoracic echocardiography (SONOS 2000 Hewlett Packard; Palo Alto, CA; or Acuson Sequoia system; Siemens; Mountain View, CA). The data were stored, and subsequent off-line calculations were done for the assessment of RV pressure overload. An examination was performed with the patient in the left supine position. The enddiastolic dimension of the RV and left ventricle (LV) were measured in the apical four-chamber view at the onset of the R wave of a monitored ECG tracing. Subsequently, the enddiastolic RV diameter/LV diameter ratio (RV/LV) was calculated. After measuring the peak velocity of tricuspid valve regurgitation with continuous Doppler echocardiography, the tricuspid peak systolic gradient was calculated according to the simplified Bernoulli formula. The acceleration time of pulmonary ejection was measured with pulsed Doppler echocardiography in the RV outflow tract. The dimensions of the inferior vena cava (IVC) were measured during expiration from the subcostal approach.
Biochemical Assays
Blood samples were collected from an antecubital vein at hospital admission and were repeated three times at 6-h intervals for the evaluation of plasma cTnT concentrations, creatine kinase isoenzyme MB (CKMB) and creatine kinase (CK) activities, and activated partial thromboplastin time (APTT) where appropriate. Samples for the determinations of cTnT were centrifuged, and plasma was frozen until assays were performed. cTnT levels were measured quantitatively (electrochemiluminescence method ECLIA; Roche; Mannheim, Germany) [detection limit, Ͼ 0.01 ng/mL]. Values of Ͻ 0.01 ng/mL, according to the manufacturer's data, were found in 99% of the healthy population. Detectable concentrations of cTnT (Ͼ 0.01ng/mL) were regarded as indicating myocardial injury. CKMB and CK activities were determined using routine laboratory methods (Ektachrome Clinical Chemistry Slides; Kodak; Rochester, NY). Increased plasma activity of CKMB of Ͼ 9U/L, with its simultaneous relative activity of total CK of Ͼ 6% was regarded as being indicative of myocardial injury. Managing physicians were unaware of the cTnT results, therefore the results of troponin measurements did not influence the choice of therapy. The protocol for this study was approved by the local institutional bioethical committees. All participating patients gave their informed consent.
Statistical Analysis
Values are expressed as the mean Ϯ SD. The Student t test or the Wilcoxon test were used for the mean comparison. The Fisher exact test was used to compare discrete variables. Univariate odds ratio (OR) analysis and multivariate stepwise logistic regression were performed to assess the influence of parameters on the in-hospital mortality rate and on the combined end point, which included at least one from the following in-hospital adverse clinical events: death; cardiopulmonary resuscitation; thrombolysis; and need for IV catecholamine infusion.
Results
Clinical Data
Before entering the study, no patient was in shock or required catecholamine infusion, no patient had undergone cardiopulmonary resuscitation, or had received ventilation. At hospital admission, the mean systolic BP for the whole group was 122.3 Ϯ 22.4 mm Hg, varying from 90 to 170 mm Hg, with a mean heart rate of 100.1 Ϯ 19.3 L/min.
According to the results of echocardiographic examination, the study population was characterized by an enlarged RV with mean end-diastolic RV/LV ratio of 1.03 Ϯ 0.29 (range, 0.54 to 1.71). A Doppler echocardiographic examination allowed the measurement of the acceleration time of pulmonary ejection in 42 of 62 patients (mean, 62.12 Ϯ 20 ms; range, 39 to 125 ms). The peak systolic velocity of the systolic tricuspid regurgitation jet could be measured in 37 patients, and mean calculated peak systolic tricuspid gradient was 42.6 Ϯ 14.7 mm Hg (range, 19 to 80 mm Hg).
Biochemical Indexes of Myocardial Injury
Plasma cTnT levels of Ͼ 0.01 ng/mL were detected at hospital admission in 29 patients (45.3%) [mean, 0.095 Ϯ 0.085 ng/mL; range, 0.014 to 0.339 ng/mL]. Interestingly, repeat assays found elevated plasma cTnT levels in an additional three patients. In two patients, the second determination indicated myocar-dial injury, while in one patient only the fourth assay revealed an increased plasma concentration of troponin T. Altogether, plasma cTnT levels were elevated in 32 of the studied patients (50%; cTnT[ϩ] group) [ Table 1 ]. The mean maximal plasma concentration of cTnT was 0.119 Ϯ 0.13 ng/mL (range, 0.014 to 0.423 ng/mL). The cTnT(ϩ) group, when compared with patients without elevations of cTnT concentrations (cTnT[Ϫ] group), was markedly older and presented slightly, but significantly, lower systolic BP values. However, the incidence of coronary heart disease and coexisting diseases (ie, congestive heart failure, malignancy, and chronic obstructive lung disease) was similar in both groups.
Standard 12-lead ECG tracings showed negative T waves in the precordial leads in 39 patients (60.1%). Interestingly, these ECG abnormalities were significantly more frequent in the cTnT(ϩ) group than in the cTnT(Ϫ) group (81.3% vs 40.6%, respectively; p ϭ 0.003).
The end-diastolic RV/LV was statistically significantly higher in the cTnT(ϩ) group compared to the group without elevations of plasma troponin (1.2 Ϯ 0.26 vs 0.88 Ϯ 0.24, respectively; p ϭ 0.0004). Interestingly, other echocardiographic parameters, such as the dimensions of the IVC and the tricuspid valve peak systolic gradient, did not differentiate the two groups. Although cTnT concentration determinations indicated myocardial injury in 50% of the patients investigated, abnormal results of plasma CKMB activities were found in 17 patients (26.5%).
Treatment and Clinical Outcome
Initially, all patients who were investigated received anticoagulation therapy with an IV infusion of unfractionated heparin, with the dose adjusted for APTT (APTT, 1.5 to 2.0 times control values) or received subcutaneous low-molecular-weight heparin in a body weight-adjusted dose. The decision to start thrombolysis was based on the clinical assessment of the individual patient by the physician in charge. A decrease in systolic systemic BP to Ͻ 90 mm Hg, the progressive acceleration of heart rate, or respiratory insufficiency was considered to be a potential indication for such aggressive treatment. However, the decision was influenced by coexisting contraindications, which were assessed individually by the physician in charge. Altogether, eight patients (12.5%) received thrombolysis with 1.5 million units IV streptokinase over 2 h. When the control APTT decreased to three times that of control subjects, IV heparin therapy was restarted.
Despite treatment, 8 of 64 patients died during hospitalization (in-hospital mortality rate, 12.5%). Irreversible RV failure was diagnosed in six patients, while in two others recurrent fatal PE was clinically suspected. Thrombolysis was used with the same frequency in survivors and nonsurvivors (12.5%). The combined end point occurred in 15 patients (23.4%). This group comprised eight patients who died (in all patients, IV catecholamine therapy was administered, with cardiopulmonary resuscitation performed in seven patients), and seven other patients underwent thrombolysis, which in one case was accompanied by successful cardiopulmonary resuscitation and the administration of IV vasopressor agents.
All deaths occurred in the troponin-positive group. Interestingly, in one patient the first three assays were negative. The in-hospital mortality rate reached 25% in the troponin-positive group, while all patients without this sign of myocardial injury survived (mortality rate, 0%) [ Table 2 ]. However, it should be noted that as many as 42% of survivors also presented with plasma cTnT levels of Ͼ 0.01 ng/mL. Moreover, there were no differences in the mean peak plasma concentrations of troponin between survivors with present biochemical signs of myocardial injury and nonsurvivors (0.124 ϩ 0.131 vs 0.105 ϩ 0.133 ng/mL, respectively; difference not significant). An OR analysis suggested that detectable plasma cTnT concentrations of Ͼ 0.01 mg/mL had the most marked impact on short-term prognosis (OR, 21; 95% confidence interval [CI], 1.2 to 389). Among clinical variables, only older age was related to adverse outcome in patients with nonmassive PE (OR, 1.09; 95% CI, 1.01 to 1.10), while neither systolic BP nor heart rate assessed at hospital admission influenced the short-term outcome. An analysis of the echocardiographic data showed that there were no differences in RV/LV ratio, the dimension of the IVC, and the acceleration time of pulmonary ejection between survivors and nonsurvivors. However, elevated tricuspid valve peak systolic gradient values indicated a worse prognosis (OR, 1.09; 95% CI, 1.02 to 1.16).
A combined end point occurred in 15 patients. There were no differences in age, systolic BP, concomitant diseases, heart rate, or echocardiographic data between the group without any important inhospital complications and the group that had experienced a clinical adverse event (Table 3) . In a univariate analysis, a detectable cTnT concentration was found to predict the occurrence of combined clinical adverse events (OR, 24.1; 95% CI, 2.9 to 200). In a multivariate stepwise regression analysis with various parameters (including age, systemic systolic BP, and RV/LV), only elevated plasma cTnT level predicted an adverse in-hospital course (OR, 20.1; 95% CI, 2.3 to 185.8).
Discussion
Shock or systemic hypotension with systolic BP Ͻ 90 mm Hg are generally accepted indications for urgent thrombolysis in patients with acute PE. 10 Although it has been reported that the in-hospital mortality rate in a subgroup of normotensive patients with signs of RV pressure overload on echocardiography may be as high as 12.6 to 15.9%, 6, 7 controversies exist about whether those patients should receive thrombolysis or anticoagulation therapy alone. 11 Moreover, recent French retrospective study 15 failed to demonstrate the superiority of thrombolysis in preventing death in normotensive patients with echocardiographic signs of RV overload, which was arbitrarily defined as an enddiastolic RV/LV of Ͼ 0.6. The presence of fatal intracranial hemorrhages, which were present in 3.1% of the group that underwent thrombolysis, outweighed the benefit of aggressive therapy for mortality reduction. 15 Although, in the Management Strategies and Prognosis in Pulmonary Embolism Study 3, 12 thrombolysis was found to affect favorably the clinical course of patients with major PE who had appeared to be hemodynamically stable at presentation, it did not reduce in-hospital mortality. This may suggests that hemodynamic and echocardiographic data may not be sufficient for precise risk stratification in this group. Levels of cardiac troponins, which are specific markers of myocardial injury, have been reported to be elevated in patients with acute coronary syndromes and have proven to be useful in their risk stratification. Increased concentrations of cTnT have been reported in 32% and 37% of patients with PE, respectively, especially those who have experienced massive PE, or those with echocardiographic signs of RV overload. 4, 16 Elevated cTnT concentrations also have been observed in patients with PE, mostly with RV dilation. 17 Even more importantly, Giannitsis et al 4 found elevated plasma troponin levels to be an independent risk factor for fatal outcome from PE. However, their study also included patients with clinically massive PEs, some of whom had experienced cardiac arrest or undergone cardiopulmonary resuscitation. We checked on whether the assessment of cTnT levels might help to define a high-risk group among normotensive patients with acute PE.
The present study enrolled patients who were hemodynamically stable at hospital admission (systolic BP, Ն 90 mm Hg). Elevated cTnT plasma concentrations were found in 50% of 64 investigated cases. This high detection rate of the specific marker of myocardial injury is caused, in our opinion, by a highly sensitive biochemical assay with a detection limit of 0.01 ng/mL. In a previously published study 4 that assessed cTnT levels in patients with PE, much less sensitive qualitative assays were used with a detection limit of 0.1 ng/mL. If this detection limit had been used in the present study, myocardial injury would have been diagnosed in merely 12 patients (18.8%) and in 4 of 8 nonsurvivors only. In addition, the repeat assays that were performed in the present study also increased the number of patients in the troponin-positive group. In contrast to a typical acute myocardial infarction, which usually is caused by an abrupt cessation of coronary blood flow, myocardial injury in a patient with PE most probably depends on various hemodynamic factors. Decreased cardiac output resulting from diminished LV preload, concomitant hypoxemia, and systemic hypotension affect both left and right coronary flow, and therefore limit oxygen supply even in patients with normal coronary arteries. However, an increased RV pressure or high wall tension in a dilated, overloaded RV may specifically increase the oxygen demand of the right myocardium and therefore may further predispose it to ischemic injury. This phenomenon indicates that myocardial damage in a patient with PE may be gradual, extended over a longer period of time even in patients with unchanged coronary arteries. 3 Therefore, a single cTnT assay may not detect deferred myocardial damage in patients who have experienced PE, and repetitive plasma cTnT level determinations are suggested. Interestingly, the negative T waves that were observed in the precordial lead were significantly more frequent in the cTnT(ϩ) group than in subjects with no biochemical sign of myocardial injury (81.3% vs 40.6%, respectively; p Ͻ 0.005). This observation suggests that this ECG finding reflects true myocardial injury. Our findings also support a recent statement 18 that PE should be considered in the differential diagnosis of patients presenting with chest pain, abnormal ECG findings, and elevated cardiac troponin levels.
Interestingly, all eight deaths that were observed during hospital stay occurred in the troponin-positive group. Thus, the in-hospital mortality rate reached 25% in the cTnT(ϩ) group, while all patients without signs of myocardial injury survived. Although older age moderately influenced the clinical outcome in patients with nonmassive PE, decreased systemic BP and tachycardia showed no significance. Moreover, the OR analysis suggested that elevated plasma cTnT level was the strongest marker of poor short-term prognosis. Unfortunately, although it is a highly sensitive indicator of patients who are at an increased risk of death, cTnT was a nonspecific marker of poor outcome. We tried to find which clinical, echocardiographic, or biochemical parameters predict a complicated in-hospital course, which was defined as at least one of the following conditions: death; thrombolysis; cardiopulmonary resuscitation; and a need for catecholamines infusion. Interestingly, elevated plasma cTnT level was the only variable indicating the incidence of adverse events both in univariate and multivariate logistic analyses (OR, 24.1; 95% CI, 2.9 to 200). Our data are consistent with those of a very recently published study, which also showed that cardiac troponin levels stratify the risk of predominantly hemodynamically stable patients who have experienced major PE. 16 The authors found that elevated cTnT levels, especially those Ͼ 0.1 ng/mL, markedly increased the risk of mortality (OR, 6.5; 95% CI, 1.11 to 38.1) and complicated in-hospital course (OR, 8.7; 95% CI, 2.6 to 29.5). 16 
Clinical Implications
Although no formal recommendations can be made, in our institutions patients with submassive PE, which was defined according to the criteria of the European Society of Cardiology, 10 are monitored in the ICU and initially receive heparin therapy alone. The plasma troponin level is determined at hospital admission. Patients with signs of myocardial injury form a high-risk group and are considered for thrombolysis. However, the decision about aggressive therapy is strongly influenced by assessment of www.chestjournal.org CHEST / 123 / 6 / JUNE, 2003 the individual risk of bleeding. Patients without elevated plasma cTnT levels continue to receive anticoagulation therapy. If clinical deterioration or no improvement after several hours is observed, repeat assessments of plasma cTnT levels are performed. In patients with elevated cTnT levels, thrombolytic therapy is reconsidered. The remaining patients continue receiving anticoagulation therapy alone with regular clinical assessment. However, a prospective trial is needed to assess the clinical value of this management strategy.
Conclusion
Patients with PE and detectable plasma cTnT levels on repeat assays are at significant risk for a complicated clinical course and fatal outcome. Therefore, cTnT(ϩ) patients with PE should be regarded as a high-risk group.
